Cameron's PhD studies will continue for four years and will assess the effectiveness and safety of the new stroke drugs the Thrombosis team is developing. His research will measure how well these drugs can thin the blood and break down blood clots in arteries, and even their potential to prevent formation of the initial blood clot. He will also observe the bleeding risk of these drugs compared to existing blood thinners used in clinics to ensure they are safe to be used in stroke patients.
Header image: Cameron Trought, Thrombosis Group